Kenneth Sternberg, DO
Interventional Cardiology · Fishersville, VANPI 1871566190
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,128 of the $53,558 with a category attached, or 80.5%. Boehringer Ingelheim accounts for 76.2% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2021 at $17,801 and has fallen 95.9% since, to $729 in 2025. Among interventional cardiology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 320 payments — averaging $167.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$41K
- Lilly USA, LLC$5K
- Medtronic$2K
- Penumbra, Inc.$1K
- Edwards Lifesciences$770
- Philips North America LLC$631
- plus $3K from 27 others
What the payments were for
- Consulting fees$9442%
- Speaking & faculty fees$43,12881%
- Travel & lodging$1,2352%
- Food & beverage$8,11415%
- Education$1370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 122 | $40,785 |
| Lilly USA, LLC | 6 | $4,778 |
| Medtronic(2 entities) | 44 | $2,265 |
| Penumbra, Inc. | 7 | $1,169 |
| Edwards Lifesciences | 9 | $770 |
| Philips North America LLC | 10 | $631 |
| Boston Scientific | 13 | $467 |
| Abbott | 7 | $334 |
| Bard Peripheral Vascular, Inc. | 5 | $261 |
| Pfizer | 13 | $229 |
| Novartis | 12 | $215 |
| AstraZeneca | 9 | $199 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $186 |
| Amgen | 10 | $172 |
| Abiomed | 6 | $140 |
| Regeneron Healthcare Solutions, Inc. | 9 | $132 |
| Johnson & Johnson | 6 | $108 |
| Vifor (international) Ltd. | 1 | $102 |
| Astellas Pharma US Inc | 1 | $100 |
| Shockwave Medical, Inc | 1 | $87 |
| Livanova USA, Inc. | 2 | $77 |
| Corindus Inc. | 1 | $69 |
| Chiesi USA, Inc. | 4 | $59 |
| Inari Medical, Inc. | 1 | $36 |
| Cardiva Medical, Inc. | 1 | $29 |
| Novo Nordisk | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 2 | $24 |
| Cvrx, Inc. | 1 | $24 |
| Stryker | 1 | $23 |
| Bayer | 1 | $22 |
| Elutia, Inc. | 1 | $16 |
| Cardiovascular Systems Inc. | 1 | $15 |
| Teleflex LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$44,144
- Indigo$1,017
- TrailBlazer$420
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$344
- ClosureRFS$280
- ONYX FRONTIER$229
- IGT D Peripheral$198
- VENOVO$168
- XIENCE SIERRA$141
- IGT D Coronary$137
- 3F$122
- SYNERGY$120
- COREVALVE EVOLUT R$108
How this compares
$53,558 in reported general payments places this provider in the 90th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 120 | $180,009 |
| EliquisApixaban | 123 | $149,709 |
| XareltoRivaroxaban | 46 | $47,744 |
| EntrestoSacubitril/Valsartan | 32 | $44,295 |
| Praluent PenAlirocumab | 14 | $18,665 |
| Atorvastatin Calcium | 285 | $2,427 |
| Metoprolol Succinate | 183 | $2,292 |
| ClopidogrelClopidogrel Bisulfate | 192 | $2,114 |
| Losartan Potassium | 128 | $1,293 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 11 | $1,251 |
| Ezetimibe | 28 | $1,019 |
| Rosuvastatin Calcium | 74 | $833 |
| Lisinopril | 91 | $577 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 46 | $568 |
| Metoprolol Tartrate | 91 | $489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $40,785 | $180,009120 claims |
| PfizerEliquis | $229 | $149,709123 claims |
| Johnson & JohnsonXarelto | $108 | $47,74446 claims |
| NovartisEntresto | $215 | $44,29532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Fishersville
- April ShewmakeFishersville$18K
- Deepak TalrejaVirginia Beach$1.5M
- Rajiv TayalFredericksburg$984K
- Gansevoort DunningtonRichmond$440K
- Matthew SummersNorfolk$308K
- Noah JonesFalls Church$238K
- Michael GenVirginia Beach$207K
- Jeremy BockLeesburg$202K
- Wayne BatchelorFalls Church$196K
- Matthew SherwoodFalls Church$193K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.